Development Pipeline
Trefoil has two active pre-clinical development programs for TTHX1114 for the treatment of corneal diseases of both the back and front surface of the cornea.
The lead indication is for the treatment of endothelial dystrophy, including Fuchs Dystrophy, which is a genetic condition that leads to the loss of endothelial cells on the back surface of the cornea. The intracameral injectable formulation of TTHX1114 is designed to renerate the endothelial cell layer and reduce or eliminate the symptoms associated with this condition that leads to the loss of vision.
The second development program is focused on a topical formulation of TTHX1114 for the treatment of ulcerative conditions affecting the epithelial cell layer on the front surface of the cornea.